# A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

> **NCT05564039** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 282 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT05564039
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-30
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-08-12
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564039, "A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05564039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*